Weinberg E D
Department of Biology, Indiana University, Bloomington 47405, USA.
Eur J Cancer Prev. 1996 Feb;5(1):19-36.
Numerous laboratory and clinical investigations over the past few decades have observed that one of the dangers of iron is its ability to favour neoplastic cell growth. The metal is carcinogenic due to its catalytic effect on the formation of hydroxyl radicals, suppression of the activity of host defence cells and promotion of cancer cell multiplication. In both animals and humans, primary neoplasms develop at body sites of excessive iron deposits. The invaded host attempts to withhold iron from the cancer cells via sequestration of the metal in newly formed ferritin. The host also endeavours to withdraw the metal from cancer cells via macrophage synthesis of nitric oxide. Quantitative evaluation of body iron and of iron-withholding proteins has prognostic value in cancer patients. Procedures associated with lowering host iron intake and inducing host cell iron efflux can assist in prevention and management of neoplastic diseases. Pharmaceutical methods for depriving neoplastic cells of iron are being developed in experimental and clinical protocols.
在过去几十年里,众多实验室研究和临床调查发现,铁的一个危害在于它能够促进肿瘤细胞生长。这种金属具有致癌性,因为它对羟基自由基的形成具有催化作用,会抑制宿主防御细胞的活性,并促进癌细胞增殖。在动物和人类中,原发性肿瘤都在铁过度沉积的身体部位发生。受侵袭的宿主会试图通过将金属螯合到新形成的铁蛋白中来阻止癌细胞获取铁。宿主还会努力通过巨噬细胞合成一氧化氮来从癌细胞中提取金属。对机体铁和铁结合蛋白进行定量评估对癌症患者具有预后价值。降低宿主铁摄入量和诱导宿主细胞铁外流的相关程序有助于肿瘤疾病的预防和管理。在实验和临床方案中,正在研发剥夺肿瘤细胞铁的药物方法。